PSYLO-3001

Last updated
PSYLO-3001
Clinical data
Other namesPSYLO3001; Psylo-3001
Routes of
administration 		Unspecified [1]
Drug class Non-hallucinogenic serotonin 5-HT2A receptor agonist

PSYLO-3001, or Psylo-3001, is a non-hallucinogenic serotonin 5-HT2A receptor agonist and psychoplastogen which is under development for the treatment of depressive disorders, generalized anxiety disorder, and social phobia (social anxiety disorder). [1] [2] [3] Its route of administration is unspecified. [1] The drug is being developed by Xylo Bio (previously Psylo). [1] [2] As of January 2025, it is in the preclinical research stage of development. [1] [2] PSYLO-3001's chemical structure does not yet appear to have been disclosed. [1]

References

  1. 1 2 3 4 5 6 "PSYLO 3001". AdisInsight. 21 January 2025. Retrieved 16 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on PSYLO-300X with Synapse". Synapse. 25 January 2025. Retrieved 16 February 2025.
  3. ↑ "Next generation neuroscience for transformative treatments". PSYLO. 28 October 2024. Retrieved 16 February 2025.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.